Imophoron Announces European Grant of Key ADDomer Technology Patent
Granted patent provides exclusivity for ADDomer-based treatments until 2036
BRISTOL, UK – 05 December 2023 – Imophoron, a biopharmaceutical company developing thermostable nanoparticle vaccines using its ADDomer™ platform, today announces the European Patent Office's (EPO) recent grant of a pivotal patent.
The patent number EP3436591, entitled “Adenoviral coat protein-derived delivery vehicles”, is exclusively licensed to Imophoron from CNRS (Centre National de la Recherche Scientifique) and EMBL (European Molecular Biology Laboratory) and encompasses fundamental claims related to the use of multiple ADDomer scaffolds for vaccine development. Notably, the period of exclusivity extends until 2036, providing Imophoron with a robust foundation for continued innovation.
Richard Bungay, Chief Executive Officer of Imophoron, commented: “We are delighted to receive confirmation of the grant of our key technology patent in Europe, securing a substantial exclusivity period. Combined with our previously granted US patent, Imophoron now holds a robust intellectual property position. This positions us to pioneer the development of intrinsically thermostable vaccines, not only to combat viral infections but also to address critical unmet medical needs in other areas such as oncology.”
For further information, please visit www.imophoron.com or contact:
Richard Bungay, Chief Executive Officer
Imophoron was founded in 2017 and has developed a thermostable nanoparticle platform, ADDomer, a disruptive technology for the development of vaccines. The ADDomer platform is focused initially on the development of vaccines to combat present and future infectious diseases, and also has significant potential to treat diseases with high unmet needs such as oncology. The ADDomer platform is based on a self-assembling thermotolerant protein that permits rapid insertion of large numbers of epitopes in a single particle. Imophoron is building a pipeline of thermostable, nanoparticle ADDomer vaccines, including multivalent approaches, to address critical medical challenges that impact communities worldwide.